The clinical introduction of the immunosuppressive drug cyclosporinein the early 1980s revolutionized the field of organ transplantation.The adoption of cyclosporine-based immunosuppressive regimensdramatically improved survival among patients who received nonrenalallografts. Twenty years later, cyclosporine and tacrolimus(another inhibitor of calcineurin — a key enzyme involvedin T-cell activation)1 remain the cornerstone of immunosuppressivetherapy for most patients who receive nonrenal transplants.
Not surprisingly, given the procedures involved, transplantationof nonrenal organs can be associated with acute renal failure.During the past two decades, however, it has become apparentthat chronic renal failure is also an important complication.. . . [Full Text of this Article]
Source Information
From the Department of Medicine, Brigham and Women's Hospital, Boston (C.M.); and the Transplantation Center, Departments of Medicine and Surgery, Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland (M.P.).
This article has been cited by other articles:
Mudge, G. H. Jr
(2007). Sirolimus and Cardiac Transplantation: Is It the "Magic Bullet"?. Circulation
116: 2666-2668
[Full Text]
Chandrakantan, A., de Mattos, A. M., Naftel, D., Crosswy, A., Kirklin, J., Curtis, J. J.
(2006). Increasing Referral for Renal Transplant Evaluation in Recipients of Nonrenal Solid-Organ Transplants: A Single-Center Experience. CJASN
1: 832-836
[Abstract][Full Text]
Humphreys, B. D., Soiffer, R. J., Magee, C. C.
(2005). Renal Failure Associated with Cancer and Its Treatment: An Update. J. Am. Soc. Nephrol.
16: 151-161
[Full Text]
Previous
